Stocks · News reference
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. This is a 63.33 percent increase over losses of $(0.30) per share
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-06 AccNo: 0001213900-26-086190 Size: 12 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarRelmada Therapeutics, a clinical-stage biotechnology company, announced its addition to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026. The company's CEO attributed the achievement to robust 12-month data for its lead candidate NDV-01 in NMIBC treatment and a well-capitalized balance sheet.
Read original at globenewswire-incRelmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today
Read original at benzinga